|Bid||0.0000 x 2200|
|Ask||0.0000 x 2900|
|Day's Range||1.4600 - 1.6200|
|52 Week Range||1.4500 - 7.5000|
|Beta (5Y Monthly)||2.12|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced that Daniel J. O'Connor, President and Chief Executive Officer of OncoSec, will present a company overview at the 31st Annual Piper Jaffray Healthcare Conference on Thursday, December 5, 2019, at 1:30 p.m. Eastern Time in New York, NY.
During Thursday’s recap, I touched on why I think an excess of secondary offerings might be part of the reason for the faltering momentum. Four of the stocks I traded in the week, Can Fite Biopharma ADR (NYSE: CANF), Obalon Therapeutics Inc. (NASDAQ: OBLN), MYnd Analytics Inc. (NASDAQ: MYND) and OncoSec Medical Inc. (NASDAQ: ONCS) each announced a secondary offering. The net effect of these offerings is more share supply, less demand and a growing reticence amongst traders to buy into cheaper stocks like CANF and OBLN for fear of getting caught in a news halt and losing their shirts.
It's Wednesday morning and traders are talking about the potential for the Fed to cuts rates if inflation dissapoints and also the AmCham China chairman Tim Stratford's comments that some of its members are worried about China's response to the U.S. adding Huawei to its 'entity list', which hurts the tech company's ability to do various […]
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We really hate to see fellow investors lose their hard-earned money. Imagine if you held OncoSec Medical Incorporated (NASDAQ:ON...